NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Victor Moreno
Fundacion Jimenez Diaz - / Spain
Others
AD Scientific Index ID: 4990954
Fundació Jimenez Diaz
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Victor Moreno's MOST POPULAR ARTICLES
1-)
The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial SK Sandhu, WR Schelman, G Wilding, V Moreno, RD Baird, S Miranda, ... The lancet oncology 14 (9), 882-892, 2013 5822013
2-)
Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ... Journal of Clinical Oncology 33 (30), 3401-3408, 2015 3542015
3-)
First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsD Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ...Clinical cancer research 21 (1), 77-86, 20152912015
4-)
KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung MetastasisP Cejas, M Lopez-Gomez, C Aguayo, R Madero, J de Castro Carpeno, ...PloS one 4 (12), e8199, 20091972009
5-)
Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary …J Tabernero, I Melero, W Ros, G Argiles, A Marabelle, ME Rodriguez-Ruiz, ...Journal of Clinical Oncology 35 (15_suppl), 3002-3002, 20171692017
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept